As Li Mu thought, another real blood vessel model appeared in front of him. Then, as his thought moved again, this real blood vessel with blood flowing in it showed a very serious blood clot in the deep veins of the lower limbs.
Once the deep vein thrombosis of the lower limbs falls off, it will travel in the body veins and eventually lead to severe pulmonary embolism. In addition, it can also cause various diseases.
Therefore, this can be regarded as a very high-risk thrombosis situation.
Later, in the simulated world, Li Mu's person appeared, and a syringe appeared in his hand.
The drug in the syringe is RSCA liquid.
In the simulation of the real universe environment, once the subject of the experiment is determined, no other experiments can be carried out.
For example, now that he has determined that the topic is fluid dynamics analysis of blood vessels, he can no longer study how to synthesize new drugs.
However, he was still able to test the effects of various thrombolytic drugs in this experiment.
As long as he knows the chemical composition of these thrombolytic drugs.
It's a small loophole that can be exploited.
As his mind moved again, the body of the simulated man in front of him reappeared from the transparent state, and then he found the buttock injection area and performed a subcutaneous injection.
After the injection was completed, Li Mu began to speed up the time in the simulated world while paying close attention to the simulator's blood clots.
Just a few seconds passed, but after ten minutes actually passed, Li Mu observed that the blood clots in the deep veins of the lower limbs gradually began to disappear.
Plasminogen is activated, allowing the fibrin in the thrombus to be quickly dissolved. Even if it has not been dissolved yet, after the attachment of the RSCA component, the fibrin becomes smoother and is no longer easily separated from the platelets. Thrombus formation.
The blood vessels are unblocked again.
Li Mu showed admiration.
This kind of thrombolytic effect is indeed very good.
At least it was much better than the 123-generation thrombolytic drugs he had used before.
Before this, he had tested the effects of previous generations of thrombolytic drugs.
Judging from the current effects, these generations of thrombolytic drugs are not as good as their RSCA.
Of course, the most important thing is that RSCA can be applied to a variety of different thrombosis symptoms.
Unlike several other thrombolytic drugs that specifically target thrombotic symptoms, alteplase, for example, is mainly used to treat acute myocardial infarction and pulmonary embolism.
After observing for a while, Li Mu discovered something else to his surprise.
RSCA has a very unique thrombolytic specificity, so it basically does not cause additional bleeding symptoms.
Other thrombolytic drugs will increase the activity level of plasmin in the body, which will cause plasmin to dissolve the fibrin other than the thrombus, such as the fibrin of the blood vessel wall cells, leading to blood vessel rupture and bleeding symptoms.
This is a common complication during thrombolysis. Once serious, such as cerebral hemorrhage, it may lead to death of the patient.
Now, according to Li Mu's simulation, RSCA's specific recognition is almost able to allow it to only recognize plasminogen in the thrombus, causing it to be stimulated into plasmin without dissolving the cell wall.
This means that even those patients with a constitution prone to bleeding will be able to use RSCA!
And ordinary patients don’t have to worry about possible bleeding complications after using RSCA!
He opened his eyes and looked at Kingsley Weir next to him.
"well-done!"
After hearing the boss's encouragement, Kingsley Weir, who had just been a little confused as to why Li Mu suddenly closed his eyes, had a smile on his face.
"Of course! I said it before, you won't regret it. This is also my promise."
Li Mu smiled, then lowered his head and turned over the report in his hand again. The report did not explain that RSCA could also prevent bleeding complications.
He then said: "It seems that you still don't know that RSCA also has a very important function."
Kingsley Weir was stunned, "What's the purpose?"
Li Mu explained this function.
Kingsley Weir was stunned for a moment. How did Li Mu do it? He could discover this after reading the report?
He asked doubtfully: "How do you know this?"
Li Mu smiled. Of course, he couldn't tell the actual reason. However, after observing the "result" in the computer in his mind, he could analyze the result through data analysis.
The method is very simple, and it is enough to analyze the blood fibrinolysis level in the data.
So he took a paper and pen from the side, and after some simple calculations, he got an obvious result.
"...So, RSCA has a more unique specificity and can avoid the mislysis of fibrin."
Seeing the results of Li Mu's analysis, Kingsley Weir's eyes widened immediately, with excitement written all over his face: "You mean... you mean... We also solved all the thrombolysis problems by the way." Complications from medications?!”
"Yes." Li Mu nodded.
"A generous gift to Crab Te!"
Kingsley Weir suddenly jumped up and down in the room excitedly.
He knew the significance of this all too well.
This means that patients with thrombosis who originally had to undergo surgical thrombus removal because of bleeding symptoms or a constitution prone to bleeding can now use their RSCA!
In this way, they will invisibly expand their possible patient customer base.
Thinking of this, Kingsley Weir couldn't help but be happy.
Hey, what if that guy Skarna Slavi is ahead?
After all, it is just an ordinary fourth-generation thrombolytic drug. How can it compare with their RSCA?
Suddenly, after thinking about Skana Slavi's fourth generation thrombolytic drug, Kingsley Weir suddenly became quiet again. After thinking for a moment, he said to Li Mu: "Boss, can you pass it?" Data analysis, analyze that guy Slavi, do their thrombolytic drugs have any side effects?"
"Do you have their experimental data?"
Li Mu glanced at Kingsley Weir.
"Uh... I don't have any specific information about this, but they posted the paper to "Cell". Can you see if you can analyze some problems?"
As he spoke, Kingsley Weir took a magazine from the side, which was the latest issue of "Cell".
Soon he turned to the paper published by Skana Slavi's team.
It is about the introduction of their fourth-generation thrombolytic drug PEFF.
The active ingredients of any drug are public, as long as a patent is applied for. As for clinical trials, they generally do not conflict with the patent, so any new drug will apply for a patent first and then proceed to clinical trials.
Only the specific preparation process and excipient ratio will not be made public.
Then, Li Mu took it and started to read it.
Soon he learned the specific composition of PEFF from the paper.
He raised his eyebrows. For him, as long as he knew the specific ingredients, he could simulate it on the calculator in his mind.
Then, the mental calculator can deduce the actual effect.
So, he closed his eyes again.
When Kingsley Weir next to him saw Li Mu closing his eyes, he immediately thought that he was probably doing mental arithmetic again.
For a moment, he shouted in his heart: "Boss, use your invincible analytical ability to analyze the shortcomings of this PEFF!"
At the same time, Li Mu had already entered the simulation and began to simulate the effects of PEFF.
As the PEFF injection entered, time accelerated. After about twenty minutes actually passed, the thrombus in the simulated patient began to show signs of dissolution. Of course, the speed was not as fast as RSCA.
"However, compared with third-generation thrombolytic drugs, it is still quite good."
Li Mu squinted his eyes and thought a little in his heart.
PEFF can be taken as seriously as Pfizer, so naturally it is not a simple drug.
But as time passed, he suddenly noticed some differences.
"Huh? There seems to be something wrong with the platelets..."
"There is a certain abnormal increase in platelet activity. Although it is not too high, it increases the risk of recurrence of thrombosis..."
Li Mu's eyes suddenly narrowed.
His mind went back to the data listed in the paper.
It does seem that the viscosity coefficient of blood has increased to a certain extent, but it is not obvious.
Of course, even if it is not obvious, it should not be underestimated, because blood clots are formed little by little.
I just don’t know whether Skarna Slavi did this on purpose or accidentally.
If it was intentional, that would be terrible.
The blood clots kept coming back, so their drug could be sold again and again.
This is of course scary, but it's also scary that they can actually control the properties of the drug.
If you are not careful...
Li Mu opened his eyes.
Kingsley Weir looked at him expectantly: "Boss, how are you doing?"
Li Mu said, "It's hard to say."
Kingsley Weir was stunned: "Why is it so hard to say?"
Li Mu told Kingsley Weir about the increased blood viscosity: "I suspect that this may be caused by the increased activation of platelets."
"In other words, after using their drugs, it is very likely to cause repeated recurrence of blood clots."
Kingsley Weir was stunned for a moment.
"What?! There is such a thing?"
(End of chapter)
